Production (Stage)
C4 Therapeutics, Inc.
CCCC
$1.56
-$0.07-4.29%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 138.17% | 58.75% | 38.75% | 350.68% | -19.15% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 138.17% | 58.75% | 38.75% | 350.68% | -19.15% |
| Cost of Revenue | 20.14% | 6.98% | 12.32% | -20.63% | -22.41% |
| Gross Profit | -1.74% | -0.76% | 4.63% | 56.91% | 22.90% |
| SG&A Expenses | -9.31% | 0.74% | 11.73% | -5.93% | -6.00% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.91% | 5.40% | 12.16% | -16.86% | -17.92% |
| Operating Income | 2.08% | -0.75% | -1.57% | 42.92% | 17.79% |
| Income Before Tax | 7.19% | 0.10% | 5.25% | 50.68% | 18.46% |
| Income Tax Expenses | -- | -52.71% | -- | -- | -- |
| Earnings from Continuing Operations | 7.19% | 0.52% | 8.77% | 50.68% | 18.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 7.19% | 0.52% | 8.77% | 50.68% | 18.46% |
| EBIT | 2.08% | -0.75% | -1.57% | 42.92% | 17.79% |
| EBITDA | 2.13% | -0.63% | -1.61% | 43.43% | 17.79% |
| EPS Basic | 10.33% | 27.78% | 35.51% | 64.83% | 41.58% |
| Normalized Basic EPS | 1.90% | 27.26% | 31.39% | 60.90% | 47.51% |
| EPS Diluted | 10.33% | 27.78% | 35.51% | 64.83% | 41.58% |
| Normalized Diluted EPS | 1.90% | 27.26% | 31.39% | 60.90% | 47.51% |
| Average Basic Shares Outstanding | 3.51% | 37.76% | 41.48% | 40.25% | 39.57% |
| Average Diluted Shares Outstanding | 3.51% | 37.76% | 41.48% | 40.25% | 39.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |